Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two pipeline products relative to competition and to establish a valuation trajectory for both products at typical value-inflection points. We were also asked to consider how continued internal development may affect shareholder value compared to out-licensing, co-development or spin-out of each product.
Alacrita conducted a high level due diligence of the two projects covering:
We then benchmarked the two products against competitive technologies, exploring:
This fed through into a Monte Carlo rNPV analysis where we assessed the value at key milestones (e.g. initiation of pivotal trials, submission for approval, etc). Finally, we benchmarked the valuations against partnering and M&A comparables enabling us to develop recommendations for maximizing shareholder value.
Since our inception over a decade ago, we've conducted more than 200 major due diligence assignments, covering a wide range of life science companies, programs and therapeutics. There are few firms that can match the level of our expertise, which is bolstered by our ability to draw in expert consultants with specialized knowledge in the core area of each project we work on.